As discussed in the large cardiovascular outcome trials, SGLT2-Is should be considered foundational therapy in patients with HF and with standard HF drugs such as angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, diuretics, and beta-blockers. The gene discussed is SLC5A2; the disease is hydrops fetalis.